D.E. Shaw & Co
DGX icon

D.E. Shaw & Co’s Quest Diagnostics DGX Stock Holding History

D.E. Shaw & Co’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,100
Closed -$469K – 3961
2020
Q3 		$469K Hold
4,100
– – ﹤0.01% 3260
2020
Q2 		$467K Buy
+4,100
New +$435K ﹤0.01% 3410
2017
Q4 		– Sell
-5,300
Closed -$496K – 3591
2017
Q3 		$496K Buy
+5,300
New +$563K ﹤0.01% 2912

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

D.E. Shaw & Co's DGX Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Quest Diagnostics (DGX) stake by 97% in Q2 2026, selling an estimated $28M and leaving 4,814 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

D.E. Shaw & Co first reported a position in DGX in Q4 2013 and has held it in 44 quarters since. The position peaked at $66.5M in Q4 2021. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • D.E. Shaw & Co held 4,814 shares of Quest Diagnostics worth $1.02M as of Q2 2026.
  • D.E. Shaw & Co sold 142,913 Quest Diagnostics shares in Q2 2026, an estimated $28M.
  • Quest Diagnostics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3734 holding.
  • D.E. Shaw & Co first reported a position in Quest Diagnostics in Q4 2013 and has held it in 44 quarters since.
  • D.E. Shaw & Co's Quest Diagnostics position peaked at $66.5M in Q4 2021.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.